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Abstract
Background: Interleukin-19 (IL-19) is a newly discovered cytokine belonging to the Interleukin-10(IL-10) family. IL-19
have indispensable functions in many inflammatory processes and also can induce the angiogenic potential of
endothelial cells. The purpose of present study was to investigate the relation of serum interleukin-19 (IL-19) levels
with diabetic nephropathy (DN).
Methods: Two hundred study groups of patients with type 2 diabetes mellitus (T2DM) (109 males and 91 females)
were recruited, included normoalbuminuria(n = 102), microalbuminuria(n = 72) and macroalbuminuria(n = 26) . The
50 healthy blood donors were enrolled for the control group. All subjects were assessed for: IL-19, High-sensitivity
C-reactive protein (Hs-CRP), Cystatin C, urinary albumin excretion rate (UAE) and glycosylated hemoglobin
A1c(HbA1c).
Results: The serum IL-19 levels in DN patients were found to be significantly higher compared to controls. IL-19
levels were significantly positively correlated with Hs-CRP, Cystatin C, UAE and HbA1c(r = 0.623, 0.611,0.591 and 0.
526 respectively, P < 0.01). Multivariable logistic regression analysis showed IL-19 levels (P = 0.01) were found to be
independently associated with patients with DN.
Conclusions: IL-19 is significantly positive correlated with UAE and Cystatin C. IL-19 may play an important role
that contributes to the progression of diabetic nephropathy.
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Background
Type 2 diabetes mellitus (T2DM) is a metabolic disease.
Hyperglycemia is the apparent feature of T2DM due to
the deficiency in peripheral insulin effects (insulin resist-
ance). The development of both macrovascular and micro-
vascular complications is a primary cause of morbidity
and mortality in diabetes that rapidly leads to premature
death [1, 2]. Vascular complications are considered for the
dominant causeof the life span and the quality of life in
T2DM, and it is important to understand the risk factors
in order to prevent the development and progression of
the complications [3]. Diabetic nephropathy (DN) is a
major microvascular complication of diabetes melli-
tus(DM), it is the leading cause of end-stage renal disease.
Inflammation plays some important roles in the pathogen-
esis of DN. Leukocytes, macrophages and monocytes all
involve in the process of DN [4, 5], and proinflammatory
cytokines and inflammatory markers are strongly associ-
ated with the development of DN [6, 7].
High-sensitivity C-reactive protein (Hs-CRP), which is a
marker of inflammation, has been reported to be associ-
ated with development of DN [8]. Albuminuria is one of
the first asymptomatic clinical features of microvascular
damage in DM. It has been shown that microalbuminuria
and macroalbuminuria are associated with progressive
renal function loss [9]. Hs-CRP levels may predict the
development of albuminuria in some studies in type 1 and
type 2 DM patients [8, 10].
Interleukin-19 (IL-19) is a newly discovered cytokine
within the Interleukin-10(IL-10) family. This protein can
stimulate the production of IL-10 from human periph-
eral blood mononuclear cells [11, 12]. It has been
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reported that IL-19 can promote the T-helper2 (Th2)
response, which is associated with a wide variety of aller-
gic (i.e., asthma and atopic dermatitis [13–15], type 1
diabetes [16], and cardiovascular disease [17, 18]. IL-19
have indispensable functions in many inflammatory pro-
cesses and also can induce the angiogenic potential of
endothelial cells [19, 20].
Several recent studies have revealed that the roles of
IL-19 in development of vascular inflammatory diseases
such as atherosclerosis, restenosis, and coronary artery
transplant vasculopathy. Our previous also reported that
IL-19 is closely related to T2DM with vascular complica-
tions [21]. However, whether there are some association
between IL-19 concentration and DN have not been
revealed clearly yet. The aim of this study was to deter-
mine the concentrations of IL-19 in DN and to investi-




200 patients with type 2 diabetes mellitus (109 males
and 91 females, age 60 ± 10.3 years) from July to Decem-
ber in 2015 were admitted to this study. According to
urinary albumin excretion rate (UAE), the patients were
divided into three groups:T2DM with normoalbuminuria
(n = 102, UAE < 30 mg/24 h), T2DM with microalbumi-
nuria (n = 72, UAE: 30–300 mg/24 h) and T2DM with
macroalbuminuria (n = 26, UAE ≥300 mg/24 h). The
exclusion criteria included patients with type 1 diabetes
and those previously diagnosed with urolithiasis, patients
with confounding factors for proteinuria, recent or
current viral hepatitis or cirrhosis of liver, medical
history of clinical cardiovascular disease, chronic lung
disease, or acute or chronic infections. Fifty healthy indi-
viduals matched for age and sex with the patients were
included in the study as a control group (26 males and
24 females, age 58 ± 11 years). The study was approved
by the Human Investigation Committee of BinHai
County hospital, and written informed consent was
obtained from all the study participants. The study was
carried out in accordance with the guidelines of the
Declaration of Helsinki.
Laboratory analysis
Venous blood samples were obtained from each partici-
pant upon hospital admission. All samples were collected
in vacuum blood collection tubes with a clot activator,
which blood was centrifuged at 1000 × g and 4 °C for
10 min. Serum was separated and aliquoted then stored at
−70 °C until analysis.
IL-19 was determined by the enzyme-linked immuno-
sorbent assay (ELISA) kits((R&D Systems, Minneapolis,
MN, USA). Urinary albumin and Hs-CRP concentrations
were assessed using the particle enhanced immuoturbidi-
metric method(BNProspec, SIEMENS,Germany). HbA1c
was measured by liquid chromatography (G8-90SL,
Tosoh, Japan). Fasting plasma glucose(FPG), total choles-
terol(TC), high density lipoprotein(HDL-C) and LDL cho-
lesterol(LDL-C) were measured by enzymatically.
Statistical analysis
The results was expressed as mean ± S.D. Comparisons
between two groups were performed using Student’s t-
test upon test of normality and equality of variances.
Spearman’s or Pearson’s method correlation analysis was
carried out to determine the association of each group.
P < 0.05 was considered statistical significance. All
analyses were performed using SPSS 17.0 (SPSS, Inc.,
Chicago, IL, USA).
Results
Clinical characteristics of participants
As expected, Hs-CRP, HbA1c, UAE, Cystatin C, TC, and
triglyceride concentrations were significantly higher and
HDL-C was lower in T2DM patients compared to the
controls. Serum IL-19 concentration was significantly
higher in T2DM patients than in controls, there were
differences between T2DM subgroups (Table 1).
IL-19 levels in T2DM with normoalbuminuria,
microalbuminuria and macroalbuminuria
In 200 T2DM patients, 72 patients had microalbumi-
nuria and 23 patients had macroalbuminuria. There was
a pronounced increase in IL-19 of the macroalbuminuric
group when compared to the microalbuminuric and nor-
moalbuminuric group. We observed that there was sig-
nificant difference in concentrations of IL-19 between
T2DM patients with normo-, micro- and macroalbumi-
nuric groups (P < 0.05) (Fig. 1).
Correlation analysis
Serum IL-19 levels showed positively correlation with
HbA1c and Hs-CRP respectively (r = 0.526 and 0.623 re-
spectively, P < 0.01). There was also a strong correlation
between IL-19 and UAE,Cystatin C (r = 0.591 and 0.611
respectively, P < 0.01) (Fig. 2).
Multivariable logistic regression analyses
In multivariable logistic regression analysis, IL-19 levels
(95% CI, 20.1 to 62.9, P = 0.01) alone showed a signifi-
cant positive association with DN even after adjusting
for age, gender, hypertension, and blood fat.
Discussion
Diabetic nephropathy is a syndrome characterized by a
progressive increase in the excretion of urinary albumin,
elevated blood pressure coupled with glomerular lesions
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leading ultimately to loss of glomerular filtration and
eventually end stage renal failure [22]. Both type 1 dia-
betes and type 2 diabetes are associated with increased
risk of macro- and micro-vascular complications. Apart
from the traditional metabolic and hemodynamic risk
factors, chronic inflammation is increasingly being
regarded as a major risk factor for DN [23, 24].
Proinflammatory cytokines play an important role in
the establishment of arteriolosclerosis [25, 26] and kid-
ney injury [27, 28]. Inflammatory cytokines are involved
in the development of microvascular diabetic complica-
tions, including diabetic nephropathy [29]. IL-19 is a
recently described IL-10 family member and the amino
acid identity between IL-19 and IL-10 is 20%, but IL-19
does not share the same receptor with IL-10. From hu-
man monocytes, B and T lymphocytes, IL-19 can be de-
tected, and the expression of IL-19 can be upregulated
in these cells by inflammatory stimuli [30, 31]. It is re-
ported that IL-19 expression is inhibited in immune
cells, and our knowledge of the function of this cytokine
is from experiments performed in inflammatory cells
and which play some indispensable functions in many
inflammatory processes [32]. Cuneo et al. reported that
inflammatory cytokines and inflammatory stimuli can
prompted IL-19 to express, the expression of IL-19 is as-
cribed in injured and stimulated vascular smooth muscle
cells [33]. Our findings showed that IL-19 concentration
is elevated in patients with T2DM and IL-19 concentra-
tion is significantly higher in macroalbuminuric and
microalbuminuric patients than normoalbuminuric pa-
tients. Multivariable logistic regression analysis showed
IL-19 levels were independently associated with DN.
These results suggest that IL-19 involved in the inflam-
matory reaction and play a significant role in the pro-
gression of DN.
Chronic endothelial inflammation is a major risk
factor in the occurring of diabetic complications and has
a pathogenic role in the progression of DN [34]. High-
sensitivity C-reactive protein, which as a marker of
inflammation has been reported to be associated with
the risk of DM complications [35–37]. Yamaoka-Tojo
et al. [38] showed that CRP may deteriorate the inflam-
matory cascade in tissue injury in addition to initiating
endothelial damage and atherosclerosis. In agreement
with the previous reports, this study also showed that
Fig. 1 IL-19 levels in T2DM patients with normo-, micro- and
macroalbuminuric groups
Table 1 Clinical characteristics and research indexes between the different studied groups
Characteristics Controls T2DM T2DM with P-value
Normoalbuminuria Microalbuminuria Macroalbuminuria





























SBP (mm Hg) 127 ± 15 130 ± 16 132 ± 15 135 ± 16 138 ± 17 0.025
DBP (mm Hg) 75 ± 7 83 ± 6 81 ± 4 82 ± 5 84 ± 5 0.037
TC (mmol/L) 4.6 ± 1.0 5.7 ± 1.6 5.6 ± 1.8 5.7 ± 1.4 5.9 ± 1.5 0.825











































HbA1c (%) 5.4 ± 0.5 8.5 ± 1.8 8.3 ± 1.5 8.7 ± 2.0 8.6 ± 1.8 <0.001
Data are presented as mean ± SD, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, HDL-C high-density
lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, IL-19, interleukin-19, UAE urinary albumin excretion, HS-CRP high-sensitivity C-reactive protein
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Hs-CRP were significantly elevated in the DN group in
comparing with the control group. We also found a
positive correlation between plasma concentrations of
IL-19 and Hs-CRP. It is well known that IL-19 is
expressed in human endothelium cell can be detected in
monocytes and macrophages infiltrate the glomeruli and
/or interstitium in the kidney tissue in patients with
DM. So, infiltrating macrophages may be responsible for
increased levels of IL-19 and IL-19 contributes to the in-
flammatory response. These data further indicate that
IL-19 and inflammation reaction are closely concerned
with the progression of nephropathy.
Jennings et al. [39] reported that IL-19 significantly
correlated with estimated glomerular filtration rate
levels. In this study, IL-19 positively correlated with
cystatin C, which is a marker of renal function, and
UAE, which is a marker of renal injury respectively. Pos-
sible explanations for our finding are an association of
IL-19 with proteinuria in DN. First, elevated levels of IL-
19 may be the result of pre-existing atherosclerosis in
T2DM patients with microalbuminuria. Second, eleva-
tions of CRP and IL-19 may directly alter glomerular
function and thus be causally involved in the develop-
ment of albuminuria. Third, there is a potential link
between IL-19 and glomerular function. IL-19 may influ-
ence the metabolism of the vascular endothelium and
the glomerular basement membrane and are involved in
the etiology of microalbuminuria.
In the current study, HbA1c in the microalbuminu-
ric/macroalbuminuric diabetic group were significantly
increased compared to normoalbuminuric and control
groups. This study is in agreement with the previous
studies, which have suggested that hyperglycemia is
the driving force for the development of DN.We also
showed a positive correlation between IL-19 concen-
tration and HbA1c. Our results suggest that long-
term hyperglycemia may increase the expression of
IL-19 via stimulating endothelial cells,which result in
local inflammation and accelerate endothelial damage
and atherosclerosis.
The limitations of this study should be noted. This
cross-sectional study population is relatively small. In
addition, the present clinical study provides evidence
that the correlation between IL-19 and the progression
of DN, but the cause–effect relationship in DN is not
addressed. Therefore, the mechanism requires further
investigation.
Conclusions
The results of present study show that IL-19 levels
was significantly elevated in the patients with diabetic
nephropathy and was associated with Hs-CRP,
Cystatin C, UAE and HbA1c. The results suggest that
IL-19 has an important role in the acceleration of
glomerular injury in addition to its inflammatory
effect on this pathophysiology, and provide further in-
sights into the understanding of IL-19 as the possible
effectiveness of anti-inflammatory therapy for DN
treatment and prevention.
Fig. 2 Serum IL-19 levels were positively correlated with HbA1c (a), Hs-CRP (b), UAE (c), CystatinC (d) respectively
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